Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incannex Healthcare Inc. - Common Stock (NQ: IXHL )

1.980 UNCHANGED
Streaming Delayed Price Updated: 11:45 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incannex Healthcare Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Psyched: Steve Cohen's New Biopharma Bet, California Gov. Authorizes Medical Psychedelics & More
Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares 
Via Benzinga
Major Psychedelic Drug Stocks Continued To Decline This Week
A review of the performances of the 5 stocks in the Psychedelic Drug Stocks Index this week and since the end of August along with links to their latest news. 
Via Talk Markets
Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More
Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of... 
Via Benzinga
September Summary: Largest Psychedelic Drug Stocks Dropped 14%
Seelos Therapeutics' market capitalization dropped below $50M with the recent dramatic decline in its share price and, as such, is no longer part of the Psychedelic Drug Stocks Index. The remaining... 
Via Talk Markets
Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More
Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge 
Via Benzinga
Topics Economy
Exposures Interest Rates
Psychedelic Drug Stocks Dragged Down By 83% Collapse In SEEL Stock Price
With the 82.6% collapse of Seelos Therapeutics (SEEL) last week, the 6 psychedelic-compound-based research & development stocks in our Psychedelic Drug Stocks Index declined by 13.0%, on average, and... 
Via Talk Markets
Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More
Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next 
Via Benzinga
Exposures Product Safety
4 Of The 6 Largest Psychedelic Compound-Based R & D Stocks Had A Good Week
4 of the 6 psychedelic-compound-based research & development stocks in our Psychedelic Drug Stocks Index were up in price last week versus only 1 the previous week. The Index was up 2.4% for the week... 
Via Talk Markets
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
6 Largest Psychedelic Compound-Based R & D Stocks In Decline
The 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were down 2.6%, on average, this week and are now only up 6.5% YTD. 
Via Talk Markets
6 Largest Psychedelic Compound-Based R & D Stocks Up 4%, On Average, Last Week
The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index were UP 3.9%, on average, last week and are now only UP 9.4% YTD. 
Via Talk Markets
Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety 
Via Benzinga
August Recap: Largest Psychedelic Compound-Based R & D Stocks Down 15%
The 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were down 15.0%, on average, in August and are now only up 5.3% YTD. 
Via Talk Markets
Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player's Retreat, Fellini's LSD Creativity, Surveys, Financing & More
Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials 
Via Benzinga
6 Largest Psychedelic Compound-Based R&D Stocks Continued Downwards, On Average, This Week
Only 2 of the 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were up this week. 
Via Talk Markets
Incannex preparing psilocybin therapy FDA IND application
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) chief medical officer Dr Mark Bleakley tells Proactive the company is preparing an application to gain key regulatory approval to begin clinical trials in... 
Via TheNewswire.com
Exposures Product Safety
Cannabis Stock Gainers And Losers From August 24, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Incannex preparing psilocybin therapy FDA IND application
--News Direct-- 
Via News Direct
Exposures Product Safety
Incannex To Prepare FDA IND Application For Psilocybin-Assisted Psychedelic Psychotherapy
Psychennex Pty Ltd, a subsidiary of Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has commenced preparations of an investigational new drug (‘IND’) application to the U.S. 
Via Benzinga
Exposures Product Safety
Incannex full steam ahead towards sleep apnoea trial
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) chief medical officer Dr Mark Bleakley speaks with Proactive after the company received clearance from the US Food and Drug Administration (FDA) to begin... 
Via TheNewswire.com
Topics Cannabis
Exposures Cannabis Product Safety
Incannex full steam ahead towards sleep apnoea trial
--News Direct-- 
Via News Direct
Topics Cannabis
Exposures Cannabis Product Safety
FDA Approves Clinical Trial Of Incannex's Dronabinol-Based Drug For Obstructive Sleep Apnea
Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has received approval from the US Food and Drug Administration to conduct the company’s investigational new drug (&ls 
Via Benzinga
Exposures Product Safety
Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports
Cannabis, Psychedelics Use And Binge Drinking At All-Time High Among Adults, Teens Remain Stable, Fed Study Finds 
Via Benzinga
Topics Cannabis Economy
Exposures Cannabis Interest Rates
Bearish Sentiment Across The Cannabis Space - Check Full Movers For August 21, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Largest Psychedelic Compound-Based R&D Stocks Continue Downward Trend
The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index were down an average of 6% last week and are now down 17.2% MTD. We take a look at them in... 
Via Talk Markets
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Bullish Thursday For Marijuana Stocks - EVIO, Tetra Bio Pharma Among Top Gainers
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannabis Stock Gainers And Losers From August 16, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published 
Via Benzinga
Cannabis Stock Gainers And Losers From August 14, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.